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Change or be changed
Reﬂections of the workshop ‘Future in Medicinal Chemistry’
Ruth Brenk a,⇑, Daniel Rauh b,⇑
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b Technische Universität Dortmund, Chemische Biologie, Otto-Hahn-Strasse 6, D-44227 Dortmund, GermanyLike almost no other scientiﬁc discipline, drug discovery and
drug development improved both the quality of life as well as
the life expectancy over the last hundred years. This was mainly
driven by medicinal chemistry which is a traditional discipline
rooted in organic synthesis and concerns the discovery, develop-
ment, identiﬁcation and interpretation of the mode of action of
biologically active compounds at the molecular and cellular level.
In its modern form, medicinal chemistry ﬁnds itself sandwiched
between target discovery and clinical application and also focuses
on target identiﬁcation and target validation. However, the
complexity of drug development and successfully bringing a drug
to the market, is still facing major roads blocks and plagued by high
attrition rates and rising R&D costs. As a consequence, a whole
industry ﬁnds itself at a crossroad.
Medicinal chemistry, quo vadis? was the central question that
brought together about sixty participants to a three-day workshop
in January 2012 organized by the Medicinal Chemistry division of
the German Chemical Society (GDCh), the German Pharmaceutical
Society (DPhG) and the Swiss Chemical Society (SCS). The partici-
pants were chosen from the disciplines of medicinal chemistry,
computational chemistry, organic chemistry, chemical biology,
biology and clinical medicine to cover a diverse range of disciplines
which are of immediate relevance to modern drug discovery and
development. In addition, there was an exiting mix between
upcoming and established scientists from both academia and
industry. The remote setting of Seeon Abbey in Upper Bavaria, a
former Benedictine monastery which already served as a refuge
for Haydn and Mozart, provided an inspirational environment for
stimulating discussions, as this workshop truly held up to its
name: ﬁve impulse lectures outlined the future challenges of
medicinal chemistry in different areas and set basis and stimulus
for group discussions that were then summarized in the plenum
and further discussed. The goals of the workshop were not only
to debate on future perspectives and hot areas of Medicinal Chem-
istry, but also to bring together scientists from different disciplines
which normally would not meet in their day-to-day research rou-
tine and to facilitate setting up a network between experienced
and younger scientists from academia and industry.0968-0896  2012 Elsevier Ltd.
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Lack of clinical efﬁcacy and unexpected toxicity are still the ma-
jor causes for frustratingly high attrition rates. Dr. Tobias Gabriel
from Novartis Pharma AG, Switzerland started off by highlighting
that best-in-class selectivity is an ever more important prerequi-
site for success in drug development. The tendency to increase
the lipophilicity of a biologically active molecule in hit- and lead-
optimization counter acts in achieving this goal as nonpolar
protein–ligand interactions are often less speciﬁc and more lipo-
philic compounds are therefore often less selective. Further, he
stressed that the residence time at the receptor is an important
property of drug molecules with ideal molecules having high kon
rates (fast binding) but low koff rates (slow dissociation) to maxi-
mize the time the receptor is occupied. Increasing drug selectivity
and thereby shifting the equilibrium between wanted and side-ef-
fects as well as increasing drug-target residence times provides
relevant inspirations for more successful future compound optimi-
zation strategies. Additionally, during the subsequent discussion it
became evident that although it is generally accepted that modu-
lating more than one target is necessary to obtain a clinically rele-
vant effect, the challenge is to deﬁne which ones to hit and for
which ones selectivity is key to success. Deciphering signaling net-
work architectures and to quantify the ﬂux of information passing
these networks is one of the great challenges in fundamental basic
research to foster drug discovery. This problem lies at the heart of
systems biology. This rising discipline is in need of the develop-
ment and detailed validation of highly selective tool compounds
to chemically perturb complex network architectures in order to
discover vulnerable nodes, which can be targeted with innovative
new drugs. The shift in basic and applied research to more complex
systems also raised the controversial questions whether pheno-
typic screens can play a role in prioritizing compounds without
having to fully understand the underlying pathways and mode of
action. Further, it was questioned if it is always possible to achieve
the desired selectivity proﬁle with a single compound. Combina-
tion dosing of selective drugs, which is already clinical practice
for most kinase inhibitors in oncology should therefore be consid-
ered as alternative strategy. It was also pointed out that the
concepts and ideas on how to design inhibitors and antagonists
are rather evident, but the molecular mechanisms for activators
and agonists are much less clear and therefore rich for discovery
opportunities. With respect to target occupancy and drug-target
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understanding on how to optimize on- and off rates in a rational
way. A better understanding of the detailed energetic and kinetic
aspects of protein–ligand interactions could therefore make a big
impact in this area. Further, it was stressed that long residence
times are usually reached with covalent inhibitors. It might there-
fore be a good idea to start looking at this type of compounds
again. However, this will require considering the turnover rates
of protein re-synthesis, as fast rates will counteract the effect of
covalent inhibitors.
Extension of chemical space
The following impulse lecture was given by Professor Herbert
Waldmann, Max-Planck-Institut für molekulare Physiologie, Dort-
mund (Germany). Waldmann reminded the audience that not all
top selling drugs are rule-of-ﬁve compliant. Often forgotten
compound classes are peptides with over 70 therapeutic peptides
on the market, some of which reached blockbuster status already.
This type of compounds should therefore not be ignored when
exploring novel targets and chemical space. Another promising
compound class are macrocyclic natural products and their ana-
logues. Such complex molecules are pre-validated by nature for
biological activity and therefore represent promising starting
points for compound development. They are often rich in sp3-con-
ﬁgured centers, which distinguishes them structurally from regular
drug molecules, derived from classic medicinal chemistry endeav-
ors. Genome mining combined with metagenomics and synthetic
biology has the potential to become rich sources to isolate these
otherwise often difﬁcult to synthesise complex materials. Finally,
it should not be forgotten that also RNA molecules and their regu-
lation constitute promising drug targets. Exploiting these might
lead to completely new therapeutic approaches.
Inspired by this lecture, lively group discussions took place. A
hot topic was the question what peptides can deliver what small
molecules or biologicals cannot. Their particular place was seen
as agonists and activators for extracellular targets that otherwise
cannot be modulated. Further, peptides might also have a role to
play as tool compounds for timely target validation in vitro and
in vivo and for assay development. Especially, since due to ad-
vances in the ﬁeld, mainly driven by academia, synthesising a di-
verse set of peptides, including such containing non-natural
amino acids, was considered relatively straight forward. However,
it was pointed out that ﬁnding the right formulation for these
molecules remains a challenging task, which might limit their
therapeutic applications and restrict them to diseases for which
non-oral drug administration is acceptable.
There was a general consensus in the discussion that macrocy-
clic natural products constitute a valuable compound class for drug
discovery. The difﬁculty in obtaining pure compounds and making
analogues was identiﬁed as main reason for natural products being
less in the focus for drug discovery. Synthetic biology might offer
some solutions to these problems and it will be very exciting to
see which advances are made in the near future. In similar vein,
disappointment about RNAi not holding up to its promises as
potential therapeutics prevailed but great openness about RNA
molecules, and in particular riboswitches, as potential drug targets
persisted.
Finally, it was questioned if molecular space up to 500 Da is al-
ready thoroughly explored. While peptides and macrocyclic com-
pounds cover chemical space beyond 500 Da, many opportunities
were still seen for smaller molecules. In particular, chemical ele-
ments such as S, P, B, and Si could be used much more frequently
and also synthetic routes to new, more sp3-center rich carbon
atom containing heterocycles remain to be developed.Drug targeting and delivery
Prof. Rainer Haag, Freie Universität Berlin (Germany), intro-
duced new concepts for drug targeting and drug delivery. Numer-
ous polymer-protein conjugates such as anchoring enzymes or
therapeutically relevant proteins to polyethylene glycol derivatives
have been developed over the years and several of them received
approval by the FDA. Coupling small molecule anticancer drugs
to high molecular weight polymers through cleavable linker sys-
tems is an effective method for improving the therapeutic index
of clinically established cytostatics. Another class of polymer
therapeutics currently receiving great attention are drug-delivery
systems based on well-deﬁned multivalent and dendritic poly-
mers. However, it also became clear that targeting approaches in
the clinic i.e. by antibody conjugates would only be successful if
the mass balance between the drug and its carries is improved.
In the subsequent group discussions, the general need for new
drug formulations was also pointed out as chemistry is likely to
continue to deliver lipophilic molecules. The formulation toolbox
should contain a mix of low and high tech approaches such as for
example new solubilizers, pH sensitive formulations, dendrimers,
and targeted antibodies. The later will require investment in lin-
ker chemistry to improve loading and to develop cleavable link-
ers. To use the potential of multivalent polymer therapeutics
the fate of the carrier in the human body also has to be better
understood. Further, since these compounds are heterogeneous,
clear guidelines are needed on which methods for characteriza-
tion are sufﬁcient for subsequent approval. To drive the ﬁeld for-
ward, a consortium instead of a single company might best tackle
these issues. From a strategic point of view, it was also suggested
to better link formulation scientists with medicinal chemists. In
pharmaceutical companies, the former are often located in the
development departments whereas the later belong to the discov-
ery units. As a consequence, cross talk only starts in the late
stages of a project while it might actually beneﬁt best from a
much earlier input. Further, it was pointed out that rational tissue
design to facilitate the detailed study of transport mechanisms as
well as cell or even cellular compartment speciﬁc drug delivery
would constitute a major break-through. Consequently, there is
the great opportunity to funnel the understanding of transport
mechanisms for the exploitation of speciﬁc drug delivery. Finally,
while prodrugs come with inherent challenges such as the need
to fully characterize both prodrug and the effective compound,
this concept was proven successful in the past and a case was
made for not ruling out this approach too quickly when facing
delivery issues in drug development.
Genome analysis—ﬁnding pathways for personalized medicine
Two impulse lectures given by Professor Paul Workman, Insti-
tute of Cancer Research, London (UK) and Professor Christof von
Kalle, National Center for Tumor Diseases, Heidelberg (Germany)
centered around genome analysis and personalized medicine. Can-
cer is a disease of the genome and characterized by the accumula-
tion of somatic, tumor-speciﬁc alterations. The current explosion
in sequencing throughput and the dramatic drop in sequencing
costs have enabled researchers to fully characterize in detail genet-
ic alterations in the genomes of all major human cancer types. Such
projects allowed for the identiﬁcation of genetically activated
oncogenes as prime cancer drug targets. Clinical success stories,
exempliﬁed by HER2-ampliﬁed breast cancers that are susceptible
to treatment with HER2-targeted antibodies, chronic myeloid leu-
kemia bearing the BCR-ABL translocation that can be treated with
ABL kinase inhibitors and EGFR-mutant lung adenocarcinomas that
are shrunk by EGFR inhibitors immediately, fuel the expectations
R. Brenk, D. Rauh / Bioorg. Med. Chem. 20 (2012) 3695–3697 3697that additional drug targets will be discovered to role out targeted
cancer therapies on a wider range. However, the development of
novel agents often fails because of lack of efﬁcacy. This inherent
problem of targeted therapies highlights the importance of prop-
erly validated drug targets and stresses the need for basic disease
biology. The case of targeted therapies in cancer not only offers
opportunities for basic research, clinical development and patient
treatment, but it also highlights that the genome of a cancer
patient has to be take in account when designing clinical trials.
Most likely, the classic regime of clinical trials with efﬁcacy studies
placed in phase-II has to be rethought.
The demonstrated progress in personalized medicine in the
treatment of cancer was welcome in the group discussions. It
was also pointed out that genomics must not stay isolated but be
combined with other ‘omics’ techniques such as proteomics,
metabolomics, transcriptomics, and epigenomics to reach its full
potential. However, it remained unclear if using genome-based
personalized medicine approaches will have a similar impact in
therapeutic areas other than cancer which might have less clear
links to genome information such as diabetes, Alzheimer’s, cardio-
vascular diseases and osteoporosis. Applying information rich
technologies to non-life threatening diseases is likely to reinforce
a debate around the ethical issues connected to generating detailed
genomic information about potentially healthy individuals. The
hope is, however, that these strategies will deliver well-validated
drug targets, which will then lead to better treatment options.Conclusions
The workshop ‘Future in Medicinal Chemistry’ and its general
topic quo vadis? gave a unique opportunity to discuss the future
of medicinal chemistry with participants from a broad range of dis-
ciplines. It reinforced the distinguished role that medicinal chemis-
try plays in drug discovery but also highlighted hot topics such as
reducing toxicity by increasing compound selectivity, optimizing
the residence time of drug molecules with their receptors, explora-
tion of chemical space, both below and above 500 Da, the need for
new drug delivery systems to solubilize drug molecules and to de-
liver them to the site of action, the opportunities of genome analysisfor target identiﬁcation, drug discovery and the design of clinical
trials as well as systems chemical biology to better understand dis-
ease biology and to direct target selection. However, the question
remains on how to effectively and in which form to tackle these
challenges. For medicinal chemistry to stay at the forefront of drug
discovery the community has not only to take more risk in frontier
research to achieve major breakthroughs, it also has to invest into
excellent education of the upcoming generation. Organic synthesis
and the art of making molecules belong to the core tools every
medicinal chemist has to master. However, due to the multidisci-
plinary nature of drug discovery young scientists also need a pro-
found understanding of biological mechanisms, enzyme and
receptor functions and disease biology. Only such knowledge will
enable them to play an integral part in the development of innova-
tive new medicine. The discussions made clear, that platforms are
needed and funding models are to be invented to support interac-
tions between academia and industry to foster innovative Medici-
nal Chemistry and drug development by considering the needs of
both academia and industry. Interdisciplinary, academia driven ba-
sic research initiatives with strong ties to the pharmaceutical
industry such as the Chemical Genomics Centre of the Max Planck
Society and the BMBF (Federal Ministry of Education and Research)
funded initiative ‘Medicinal Chemistry in Dortmund’ might serve as
role models in this respect. The latter initiative for example, does
not only focus on basic research in modern, innovative drug discov-
ery, it also aims at strengthening graduate training in Medicinal
Chemistry at the Technische Universität Dortmund in cooperation
with local and global industry partners.
Overall, the three-day workshop proved to be a fantastic forum
with the right mix of excellent impulse lectures and ample time for
discussions. It not only fostered exchange of experience between
academia and industry and upcoming and established scientists
from a broad range of disciplines but it also set the foundation for
more regular meetings of this kind to shape a network which will
be crucial to take advantage of the transitions currently under way.
« The old is crumbling down—the times are changing » Wilhelm
Tell IV/2.
Medicinal chemistry, take your chances!
